Pay in 4 interest-free payments of $5.70 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
When safety measures are followed, tirzepatide has better results than other treatments
If you're struggling with dietary planning, ask your GP about referral to a registered dietitian for personalised advice
Glucagon-like peptide-1 receptor agonists (the drug class that includes semaglutide) should never be combined with other GLP-1 medications or GIP receptor agonists unless specifically prescribed as a dual-therapy compound
Similar patterns appeared in other obesity-related cancers: Non-small cell lung cancer: progression to Stage IV roughly 10% versus 22% Colorectal cancer: statistically significant reduction in progression Hepatocellular (liver) cancer: signal in the same direction A separate JAMA Oncology study by Dai and colleagues (2025), distinct from the Cleveland Clinic ASCO analysis, found about a 17% lower overall cancer incidence (hazard ratio approximately 0.83) in adults with obesity who used GLP-1 receptor agonists, with most of the signal coming from skin cancers and obesity-related solid tumors
